HIV medications produced by generic Indian manufacturer Ranbaxy Laboratories Ltd. will not be purchased under the President’s Emergency Plan for AIDS Relief (PEPFAR) until the company resolves U.S. Food and Drug Administration (FDA) violations at two of its plants, Bloomberg reports.

The program, which provides antiretroviral (ARV) medications to developing countries, will suspend funding for three Ranbaxy drugs: zidovudine, lamivudine and nevirapine.

According to the article, Ranbaxy has made efforts to improve conditions at one of its plants and, according to spokesman Charles M. Caprariello, is working with the U.S. government “to resolve all of the issues and concerns that have been raised.”